These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15834877)

  • 1. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
    Brown BK; Wieczorek L; Sanders-Buell E; Rosa Borges A; Robb ML; Birx DL; Michael NL; McCutchan FE; Polonis VR
    Virology; 2008 Jun; 375(2):529-38. PubMed ID: 18433824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
    Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
    Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
    Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
    J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine.
    Ferrantelli F; Kitabwalla M; Rasmussen RA; Cao C; Chou TC; Katinger H; Stiegler G; Cavacini LA; Bai Y; Cotropia J; Ugen KE; Ruprecht RM
    J Infect Dis; 2004 Jan; 189(1):71-4. PubMed ID: 14702155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
    Beirnaert E; Nyambi P; Willems B; Heyndrickx L; Colebunders R; Janssens W; van der Groen G
    J Med Virol; 2000 Sep; 62(1):14-24. PubMed ID: 10935983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
    Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
    Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35).
    Zhou J; Montefiori DC
    Virology; 1996 Dec; 226(1):13-21. PubMed ID: 8941318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
    Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
    J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-subtype cross-neutralizing antibodies recognize epitopes on cell-associated HIV-1 virions.
    Donners H; Davis D; Willems B; van der Groen G
    J Med Virol; 2003 Feb; 69(2):173-81. PubMed ID: 12683404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.
    Brown BK; Darden JM; Tovanabutra S; Oblander T; Frost J; Sanders-Buell E; de Souza MS; Birx DL; McCutchan FE; Polonis VR
    J Virol; 2005 May; 79(10):6089-101. PubMed ID: 15857994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization of HIV-1 subtypes: implications for vaccine formulations.
    Smith TL; van Rensburg EJ; Engelbrecht S
    J Med Virol; 1998 Nov; 56(3):264-8. PubMed ID: 9783696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.
    Geels MJ; Dubey SA; Anderson K; Baan E; Bakker M; Pollakis G; Paxton WA; Shiver JW; Goudsmit J
    J Virol; 2005 Sep; 79(17):11247-58. PubMed ID: 16103177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children.
    Buseyne F; Chaix ML; Fleury B; Manigart O; Burgard M; Blanche S; Rouzioux C; Rivière Y
    Virology; 1998 Oct; 250(2):316-24. PubMed ID: 9792842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents.
    Coplan PM; Gupta SB; Dubey SA; Pitisuttithum P; Nikas A; Mbewe B; Vardas E; Schechter M; Kallas EG; Freed DC; Fu TM; Mast CT; Puthavathana P; Kublin J; Brown Collins K; Chisi J; Pendame R; Thaler SJ; Gray G; Mcintyre J; Straus WL; Condra JH; Mehrotra DV; Guess HA; Emini EA; Shiver JW
    J Infect Dis; 2005 May; 191(9):1427-34. PubMed ID: 15809900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies.
    Rollman E; Hinkula J; Arteaga J; Zuber B; Kjerrström A; Liu M; Wahren B; Ljungberg K
    Gene Ther; 2004 Jul; 11(14):1146-54. PubMed ID: 15103320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
    Xin KQ; Sekimoto Y; Takahashi T; Mizuguchi H; Ichino M; Yoshida A; Okuda K
    Vaccine; 2007 May; 25(19):3809-15. PubMed ID: 17386962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.